Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 644 entries
Sorted by: Best Match Show Resources per page
Naltrexone in the treatment of alcohol dependence

Build and Broaden 3.0 AND Program Evaluation

Krystal JH.
GSID: Beqx1qq33I4J
JH Krystal, JA Cramer, WF Krol, GF Kirk… - … England Journal of …, 2001 - Mass Medical Soc

Background Although naltrexone, an opiate-receptor antagonist, has been approved by the Food and Drug Administration for the treatment of alcohol dependence, its efficacy is …

Cite
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001). Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine, 345(24), 1734-1739.
Krystal, John H., et al. "Naltrexone in the treatment of alcohol dependence." New England Journal of Medicine 345.24 (2001): 1734-1739.
Copy Download .nbib Format: MLA
Efficacy of naltrexone hydrochloride for preventing relapse among opiate-dependent patients after detoxification

community settings

[No authors listed]
GSID: LQez-H8kk3sJ
S Guo, Z Jiang, Y Wu - Hong Kong Journal of Psychiatry, 2001 - go.gale.com

Objective: To investigate the efficacy of naltrexone in preventing relapse of heroin addiction among Chinese patients after successful detoxification. Methods: 302 heroin addicts were …

Cite
Guo, S., Jiang, Z., & Wu, Y. (2001). Efficacy of naltrexone hydrochloride for preventing relapse among opiate-dependent patients after detoxification. Hong Kong Journal of Psychiatry, 11(4), 2-9.
Guo, S., Z. Jiang, and Y. Wu. "Efficacy of naltrexone hydrochloride for preventing relapse among opiate-dependent patients after detoxification." Hong Kong Journal of Psychiatry 11.4 (2001): 2-9.
Copy Download .nbib Format: MLA
A Rare Case of Complicated Opioid Withdrawal in Delirium Without Convulsions.

Indian journal of psychological medicine

Raj BN, Manamohan N, Hegde D, Huded CB, Pradeep J.
PMID: 28515558
Indian J Psychol Med. 2017 Mar-Apr;39(2):191-193. doi: 10.4103/0253-7176.203109.

Opioids are one of the commonly abused substances in India. Opioid withdrawal symptoms classically include severe muscle cramps, bone aches, autonomic symptoms, anxiety, restlessness, insomnia, and temperature dysregulation. However, reports of cases with delirium during withdrawal are few. A...

Cite
Raj BN, Manamohan N, Hegde D, et al. A Rare Case of Complicated Opioid Withdrawal in Delirium Without Convulsions. Indian J Psychol Med. 2017;39(2):191-193doi: 10.4103/0253-7176.203109.
Raj, B. N., Manamohan, N., Hegde, D., Huded, C. B., & Pradeep, J. (2017). A Rare Case of Complicated Opioid Withdrawal in Delirium Without Convulsions. Indian journal of psychological medicine, 39(2), 191-193. https://doi.org/10.4103/0253-7176.203109
Raj, B Neeraj, et al. "A Rare Case of Complicated Opioid Withdrawal in Delirium Without Convulsions." Indian journal of psychological medicine vol. 39,2 (2017): 191-193. doi: https://doi.org/10.4103/0253-7176.203109
Raj BN, Manamohan N, Hegde D, Huded CB, Pradeep J. A Rare Case of Complicated Opioid Withdrawal in Delirium Without Convulsions. Indian J Psychol Med. 2017 Mar-Apr;39(2):191-193. doi: 10.4103/0253-7176.203109. PMID: 28515558; PMCID: PMC5385750.
Copy Download .nbib Format: NLM
[Craving as a core symptom in substance use disorders: epidemiology, neurobiological substrates and clinical relevance].

Sante mentale au Quebec

Morissette A, Ouellet-Plamondon C, Jutras-Aswad D.
PMID: 25590542
Sante Ment Que. Fall 2014;39(2):21-37.

OBJECTIVE: Observed by physicians and often reported by patients, craving is a core symptom of addiction, although not well defined nor understood completely. In the last several years, functional imaging as well as the measurement of different biological substrates...

Cite
Morissette A, Ouellet-Plamondon C, Jutras-Aswad D. Le craving comme symptôme central de la toxicomanie : de ses fondements neurobiologiques à sa pertinence clinique. [Craving as a core symptom in substance use disorders: epidemiology, neurobiological substrates and clinical relevance]. Sante Ment Que. 0;39(2):21-37
Morissette, A., Ouellet-Plamondon, C., & Jutras-Aswad, D. (0). Le craving comme symptôme central de la toxicomanie : de ses fondements neurobiologiques à sa pertinence clinique. [Craving as a core symptom in substance use disorders: epidemiology, neurobiological substrates and clinical relevance]. Sante mentale au Quebec, 39(2), 21-37.
Morissette, Audrey, et al. "Le craving comme symptôme central de la toxicomanie : de ses fondements neurobiologiques à sa pertinence clinique." [Craving as a core symptom in substance use disorders: epidemiology, neurobiological substrates and clinical relevance]. Sante mentale au Quebec vol. 39,2 (0): 21-37.
Morissette A, Ouellet-Plamondon C, Jutras-Aswad D. Le craving comme symptôme central de la toxicomanie : de ses fondements neurobiologiques à sa pertinence clinique. [Craving as a core symptom in substance use disorders: epidemiology, neurobiological substrates and clinical relevance]. Sante Ment Que. Fall 2014;39(2):21-37. French. PMID: 25590542.
Copy Download .nbib Format: NLM
Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone.

The primary care companion for CNS disorders

Rodgman CJ, Verrico CD, Worthy RB, Lewis EE.
PMID: 25664202
Prim Care Companion CNS Disord. 2014 Aug 14;16(4). doi: 10.4088/PCC.13l01594. eCollection 2014.

No abstract available.

Cite
Rodgman CJ, Verrico CD, Worthy RB, et al. Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone. Prim Care Companion CNS Disord. 2014;16(4)doi: 10.4088/PCC.13l01594.
Rodgman, C. J., Verrico, C. D., Worthy, R. B., & Lewis, E. E. (2014). Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone. The primary care companion for CNS disorders, 16(4), . https://doi.org/10.4088/PCC.13l01594
Rodgman, Christopher J C, et al. "Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone." The primary care companion for CNS disorders vol. 16,4 (2014). doi: https://doi.org/10.4088/PCC.13l01594
Rodgman CJ, Verrico CD, Worthy RB, Lewis EE. Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone. Prim Care Companion CNS Disord. 2014 Aug 14;16(4). doi: 10.4088/PCC.13l01594. eCollection 2014. PMID: 25664202; PMCID: PMC4318662.
Copy Download .nbib Format: NLM
Adherence to Buprenorphine Maintenance Treatment in Opioid Dependence Syndrome: A Case Control Study.

Indian journal of psychological medicine

Bandawar M, Kandasamy A, Chand P, Murthy P, Benegal V.
PMID: 26664083
Indian J Psychol Med. 2015 Jul-Sep;37(3):330-2. doi: 10.4103/0253-7176.162951.

BACKGROUND: Opioid Use disorders are emerging as a serious public health concern in India. Opioid substitution treatment is one of the emerging forms of treatment in this population which needs more evidence to increase its availability and address prejudices...

Cite
Bandawar M, Kandasamy A, Chand P, et al. Adherence to Buprenorphine Maintenance Treatment in Opioid Dependence Syndrome: A Case Control Study. Indian J Psychol Med. 2015;37(3):330-2doi: 10.4103/0253-7176.162951.
Bandawar, M., Kandasamy, A., Chand, P., Murthy, P., & Benegal, V. (2015). Adherence to Buprenorphine Maintenance Treatment in Opioid Dependence Syndrome: A Case Control Study. Indian journal of psychological medicine, 37(3), 330-2. https://doi.org/10.4103/0253-7176.162951
Bandawar, Mrunal, et al. "Adherence to Buprenorphine Maintenance Treatment in Opioid Dependence Syndrome: A Case Control Study." Indian journal of psychological medicine vol. 37,3 (2015): 330-2. doi: https://doi.org/10.4103/0253-7176.162951
Bandawar M, Kandasamy A, Chand P, Murthy P, Benegal V. Adherence to Buprenorphine Maintenance Treatment in Opioid Dependence Syndrome: A Case Control Study. Indian J Psychol Med. 2015 Jul-Sep;37(3):330-2. doi: 10.4103/0253-7176.162951. PMID: 26664083; PMCID: PMC4649800.
Copy Download .nbib Format: NLM
Weight loss medications in Canada - a new frontier or a repeat of past mistakes?.

Diabetes, metabolic syndrome and obesity : targets and therapy

Wharton S, Lee J, Christensen RA.
PMID: 29042804
Diabetes Metab Syndr Obes. 2017 Oct 04;10:413-417. doi: 10.2147/DMSO.S141571. eCollection 2017.

Current methods for the treatment of excess weight can involve healthy behavior changes, pharmacotherapy, and surgical interventions. Many individuals are able to lose some degree of weight through behavioral changes; however, they are often unable to maintain their weight...

Cite
Wharton S, Lee J, Christensen RA. Weight loss medications in Canada - a new frontier or a repeat of past mistakes?. Diabetes Metab Syndr Obes. 2017;10:413-417doi: 10.2147/DMSO.S141571.
Wharton, S., Lee, J., & Christensen, R. A. (2017). Weight loss medications in Canada - a new frontier or a repeat of past mistakes?. Diabetes, metabolic syndrome and obesity : targets and therapy, 10413-417. https://doi.org/10.2147/DMSO.S141571
Wharton, Sean, et al. "Weight loss medications in Canada - a new frontier or a repeat of past mistakes?." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 10 (2017): 413-417. doi: https://doi.org/10.2147/DMSO.S141571
Wharton S, Lee J, Christensen RA. Weight loss medications in Canada - a new frontier or a repeat of past mistakes?. Diabetes Metab Syndr Obes. 2017 Oct 04;10:413-417. doi: 10.2147/DMSO.S141571. eCollection 2017. PMID: 29042804; PMCID: PMC5633321.
Copy Download .nbib Format: NLM
How Relevant is Food Craving to Obesity and Its Treatment?.

Frontiers in psychiatry

Potenza MN, Grilo CM.
PMID: 25477827
Front Psychiatry. 2014 Nov 19;5:164. doi: 10.3389/fpsyt.2014.00164. eCollection 2014.

No abstract available.

Cite
Potenza MN, Grilo CM. How Relevant is Food Craving to Obesity and Its Treatment?. Front Psychiatry. 2014;5:164doi: 10.3389/fpsyt.2014.00164.
Potenza, M. N., & Grilo, C. M. (2014). How Relevant is Food Craving to Obesity and Its Treatment?. Frontiers in psychiatry, 5164. https://doi.org/10.3389/fpsyt.2014.00164
Potenza, Marc N, and Grilo, Carlos M. "How Relevant is Food Craving to Obesity and Its Treatment?." Frontiers in psychiatry vol. 5 (2014): 164. doi: https://doi.org/10.3389/fpsyt.2014.00164
Potenza MN, Grilo CM. How Relevant is Food Craving to Obesity and Its Treatment?. Front Psychiatry. 2014 Nov 19;5:164. doi: 10.3389/fpsyt.2014.00164. eCollection 2014. PMID: 25477827; PMCID: PMC4237037.
Copy Download .nbib Format: NLM
Prolonged receptor blockade by opioid receptor probes.

Pharmaceutical research

Koman A, Kolb VM, Terenius L.
PMID: 24271359
Pharm Res. 1986 Feb;3(1):56-60. doi: 10.1023/A:1016329000518.

Opioid receptor interactions of morphinan-type opioids derivatized at the C-6 carbon were investigated. The compounds, designed as probes for studying opioid receptors, were characterized with regard to affinity for the rat brain mu receptor by competition with tritium-labeled dihydromorphine...

Cite
Koman A, Kolb VM, Terenius L. Prolonged receptor blockade by opioid receptor probes. Pharm Res. 1986;3(1):56-60doi: 10.1023/A:1016329000518.
Koman, A., Kolb, V. M., & Terenius, L. (1986). Prolonged receptor blockade by opioid receptor probes. Pharmaceutical research, 3(1), 56-60. https://doi.org/10.1023/A:1016329000518
Koman, A, et al. "Prolonged receptor blockade by opioid receptor probes." Pharmaceutical research vol. 3,1 (1986): 56-60. doi: https://doi.org/10.1023/A:1016329000518
Koman A, Kolb VM, Terenius L. Prolonged receptor blockade by opioid receptor probes. Pharm Res. 1986 Feb;3(1):56-60. doi: 10.1023/A:1016329000518. PMID: 24271359.
Copy Download .nbib Format: NLM
Heroin inhibits HIV-restriction miRNAs and enhances HIV infection of macrophages.

Frontiers in microbiology

Wang X, Ma TC, Li JL, Zhou Y, Geller EB, Adler MW, Peng JS, Zhou W, Zhou DJ, Ho WZ.
PMID: 26583016
Front Microbiol. 2015 Nov 04;6:1230. doi: 10.3389/fmicb.2015.01230. eCollection 2015.

Although opioids have been extensively studied for their impact on the immune system, limited information is available about the specific actions of opioids on intracellular antiviral innate immunity against HIV infection. Thus, we investigated whether heroin, one of the...

Cite
Wang X, Ma TC, Li JL, et al. Heroin inhibits HIV-restriction miRNAs and enhances HIV infection of macrophages. Front Microbiol. 2015;6:1230doi: 10.3389/fmicb.2015.01230.
Wang, X., Ma, T. C., Li, J. L., Zhou, Y., Geller, E. B., Adler, M. W., Peng, J. S., Zhou, W., Zhou, D. J., & Ho, W. Z. (2015). Heroin inhibits HIV-restriction miRNAs and enhances HIV infection of macrophages. Frontiers in microbiology, 61230. https://doi.org/10.3389/fmicb.2015.01230
Wang, Xu, et al. "Heroin inhibits HIV-restriction miRNAs and enhances HIV infection of macrophages." Frontiers in microbiology vol. 6 (2015): 1230. doi: https://doi.org/10.3389/fmicb.2015.01230
Wang X, Ma TC, Li JL, Zhou Y, Geller EB, Adler MW, Peng JS, Zhou W, Zhou DJ, Ho WZ. Heroin inhibits HIV-restriction miRNAs and enhances HIV infection of macrophages. Front Microbiol. 2015 Nov 04;6:1230. doi: 10.3389/fmicb.2015.01230. eCollection 2015. PMID: 26583016; PMCID: PMC4632020.
Copy Download .nbib Format: NLM
[Injectable extended-release naltrexone for the prevention of relapse to opioid dependence following opioid detoxification].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Krupitskiĭ EM.
PMID: 24988978
Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(5):64-72.

Opioid dependence is a growing, worldwide public health concern. In contrast to opioid ?-agonist (or 'substitution') maintenance treatments, injectable extendedrelease naltrexone (XR-NTX), approved in the USA and Russia, is an opioid antagonist, formulated to address nonadherence, which limits the...

Cite
Krupitskiĭ EM. Primenenie prolongirovannogo in''ektsionnogo naltreksona dlia profilaktiki retsidiva opioidnoĭ zavisimosti posle detoksikatsii. [Injectable extended-release naltrexone for the prevention of relapse to opioid dependence following opioid detoxification]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(5):64-72
Krupitskiĭ, E. M. (2014). Primenenie prolongirovannogo in''ektsionnogo naltreksona dlia profilaktiki retsidiva opioidnoĭ zavisimosti posle detoksikatsii. [Injectable extended-release naltrexone for the prevention of relapse to opioid dependence following opioid detoxification]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 114(5), 64-72.
Krupitskiĭ, E M. "Primenenie prolongirovannogo in''ektsionnogo naltreksona dlia profilaktiki retsidiva opioidnoĭ zavisimosti posle detoksikatsii." [Injectable extended-release naltrexone for the prevention of relapse to opioid dependence following opioid detoxification]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova vol. 114,5 (2014): 64-72.
Krupitskiĭ EM. Primenenie prolongirovannogo in''ektsionnogo naltreksona dlia profilaktiki retsidiva opioidnoĭ zavisimosti posle detoksikatsii. [Injectable extended-release naltrexone for the prevention of relapse to opioid dependence following opioid detoxification]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(5):64-72. Russian. PMID: 24988978.
Copy Download .nbib Format: NLM
Long-term agonist and antagonist therapy for adolescent opioid dependence: a description of two cases.

Indian journal of psychological medicine

Ranjan R, Pattanayak RD, Dhawan A.
PMID: 25336782
Indian J Psychol Med. 2014 Oct;36(4):439-43. doi: 10.4103/0253-7176.140754.

Adolescents constitute only a small percentage of treatment seekers in drug dependence treatment settings. Little research evidence is available for pharmacological treatment of adolescent opioid dependence and no prior case report is available from India. We discuss two adolescent...

Cite
Ranjan R, Pattanayak RD, Dhawan A. Long-term agonist and antagonist therapy for adolescent opioid dependence: a description of two cases. Indian J Psychol Med. 2014;36(4):439-43doi: 10.4103/0253-7176.140754.
Ranjan, R., Pattanayak, R. D., & Dhawan, A. (2014). Long-term agonist and antagonist therapy for adolescent opioid dependence: a description of two cases. Indian journal of psychological medicine, 36(4), 439-43. https://doi.org/10.4103/0253-7176.140754
Ranjan, Rajeev, et al. "Long-term agonist and antagonist therapy for adolescent opioid dependence: a description of two cases." Indian journal of psychological medicine vol. 36,4 (2014): 439-43. doi: https://doi.org/10.4103/0253-7176.140754
Ranjan R, Pattanayak RD, Dhawan A. Long-term agonist and antagonist therapy for adolescent opioid dependence: a description of two cases. Indian J Psychol Med. 2014 Oct;36(4):439-43. doi: 10.4103/0253-7176.140754. PMID: 25336782; PMCID: PMC4201802.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 644 entries